



Asymmetric total synthesis of (–)-isocelorbicol, a natural dihydroagarofuran sesquiterpenoid


Wei-Dong Z. Li,* Gang Zhou, Xiaolei Gao and Yulin Li*

National Laboratory of Applied Organic Chemistry and Institute of Organic Chemistry, Lanzhou University, Lanzhou 730000, PR China

Received 23 March 2001; revised 8 May 2001; accepted 11 May 2001

Abstract—The first enantioselective total synthesis of (–)-isocelorbicol, a naturally occurring sesquiterpene polyol of the agarofuran group, starting from optically active 9-oxo-10-*epi*- α -cyperone (**8**) is described. © 2001 Elsevier Science Ltd. All rights reserved.

In the past two decades, the plants of the *Celastraceae* family have attracted considerable attention and proven to be a rich source of characteristic hydroxylated sesquiterpene esters^{1–5} bearing a tricyclic dihydroagarofuran skeleton **1**, which have been shown to exhibit significant cytotoxic,⁶ immunosuppressive,⁷ anticancer,⁸ insect antifeedant⁹ and potent anti-HIV¹⁰ activities. The dense array of hydroxyl substitution on the decalin skeleton leads to the increasingly complex structures of this type of sesquiterpene natural products as illustrated for diol **2**,¹¹ triol **3** (isocelorbicol),¹² benzoate **4**¹³ and euonyminol **5**.¹⁴



Intrigued by their unique structure and remarkably wide range of biological activities, pioneering studies on the synthesis of agarofuran sesquiterpenoids have been reported by Büchi,¹⁵ Marshall,¹⁶ Deslongchamps,¹⁷ Heathcock,¹⁸ Huffman,¹⁹ and more recently White,²⁰ which have stimulated a great deal of interests in this area.²¹ The asymmetric synthesis of polyhydroxylated dihydroagarofuran represents a significant challenge for synthetic organic chemists. In connection with our

interests in this subject and the ongoing project on the asymmetric synthesis of bioactive sesquiterpenoids, we have reported²² in a previous Letter a stereocontrolled oxidative acetoxylation at sterically congested C-1 position of the decalin skeleton leading to a general approach for the construction of the tricyclic dihydroagarofuran skeleton **1**. Herein we describe the application of this method for the first enantioselective synthesis of isocelorbicol (**3**), a dihydroagarofuran triol isolated from the seeds of *Celastrus orbiculatus* by Smith and coworkers in 1976 with its structure elucidated¹² on the basis of spectral and chemical evidence. The


racemic syntheses of **3** have been reported by Huffman and co-workers.^{19d–f}

The retrosynthetic plan is outlined in Scheme 1, which involves (1) conversion of optically active 9-oxo-10-*epi*- α -cyperone (**8**)²² to key intermediate enone **7**, (2) hydroxylation of **7** at C-1 and cyclization to form β -dihydroagarofuran **6**, and (3) stereocontrolled reduction of keto groups and hydrogenation of $\Delta^{3,4}$ olefin of **6**.

As reported²² previously, 9-oxo-10-*epi*- α -cyperone (**8**) (54% ee), was transformed into enone **7** in four steps in good chemical yield, which was subjected to recrystal-

Keywords: isocelorbicol; dihydroagarofuran; sesquiterpenoid; asymmetric synthesis.

* Corresponding authors. E-mail: liwd@lzu.edu.cn



Scheme 1.

lization twice from a solvent mixture of ether and hexane (v/v 3:1) to afford practically optically pure **7** {mp 119–121°C, $[\alpha]_D^{25}$ –97.0 (c 0.25, CHCl_3), >98% ee²³} in 67% yield. This crucial optical enrichment of **7** allows the synthesis of the natural **3** in a highly enantioselective fashion for the first time.


Detailed synthesis of **3** was outlined in Scheme 2. Acetoxylation $[\text{Mn}(\text{OAc})_3, \text{C}_6\text{H}_6, \text{reflux}]^{22}$ of optically pure enone **7** at C-1 followed by acid-catalyzed formation of dihydroagarofuran ring furnished the enone acetate **10**, which bears the tricyclic skeleton with desired β -configured dihydroagarofuran ring of **3**.

The next stage of the synthesis requires the inversion of the hydroxyl configuration of **10** at C-9. Attempts for this purpose under Mitsunobu condition²⁴ met with failure presumably due to severe steric hindrance at C-9. An alternative way turned out to be ideal through the following two-step sequence: (1) Dess–Martin periodinane oxidation²⁵ to **11** (90%), (2) subsequent reduction with LAH in ether to give triol **12** and its C-2

epimer in a ratio of 3:1. To our disappointment, the catalytic hydrogenation (10% Pd-C, EtOH) of **12** afforded predominately 4-*epi*-isocolorbicol (**13**)^{19d} in 95% yield.

Alternatively, hydrogenation of tris-TBS silyl ether **14** (68% from triol **12** by standard silylation) and subsequent desilylation gave the desired title compound **3** (27% yield from triol **12**) along with its 4 β -epimer **13** in a ratio of ca. 10:1.²⁶ The spectral data and optical property of the synthetic **3** were consistent with those of reported for natural product.²⁷

In summary, the synthesis of natural (–)-isocolorbicol (**3**) has been achieved enantioselectively from optically active 9-oxo-10-*epi*- α -cyperone (**8**) in 12 steps as well as its 4-epimeric isomer **13** by employing a general and efficient strategy based on the oxidative introduction of acetoxy function at C-1. The strategy demonstrated here is potentially applicable for the asymmetric synthesis of other polyhydroxylated dihydroagarofurans that is underway in our Laboratory.



Scheme 2. Reagents and conditions: (a) $\text{Mn}(\text{OAc})_3$, C_6H_6 , reflux, 53%; (b) TfOH , THF, rt, 5 min, 95%; (c) Dess–Martin periodinane, CH_2Cl_2 , rt, 90%; (d) LAH, ether, 0°C, 62%; (e) H_2 , 10% Pd-C, EtOH, rt, 24 h, 95%; (f) TBSOTf, Et_3N , CH_2Cl_2 , rt, 2.5 h, 68%; (g) $n\text{-Bu}_4\text{N}^+\text{F}^-$, $\text{THF-H}_2\text{O}$, rt, 24 h, 47%. (rt = 20–25°C, TfOH = trifluoromethanesulfonic acid).

Acknowledgements

We are grateful for the financial supports from the National Natural Science Foundation of China (No. 29732060), the National Outstanding Youth Fund (No. 29925204) and the Foundation for University Key Teacher by the Ministry of Education of China.

References

- (a) Munoz, O.; Penazola, A.; Gonzales, A. G.; Ravelo, A. G.; Bazzocchi, I. L.; Alvarenga, N. L. In *Studies in Natural Product Chemistry*; Atta-ur-Rahman, Ed.; Elsevier Science: Amsterdam, 1996; Vol. 18, pp. 739–783; (b) Crombie, L.; Crombie, W. M. L.; Whiting, D. A. *The Alkaloids* **1990**, 39, 139–164.
- Bruning, R.; Wagner, H. *Phytochemistry* **1978**, 17, 1821.
- González, A. G.; Gonzalez, C. M.; Ravelo, A. G.; Fraga, B. M.; Dominguez, X. A. *Phytochemistry* **1988**, 27, 473.
- Tu, Y.-Q.; Wu, D.-G.; Zhou, J.; Chen, Y.-Z. *Phytochemistry* **1990**, 29, 2923.
- Takaishi, Y.; Tamai, S.; Nakano, K.; Murakami, K.; Tomimatsu, T. *Phytochemistry* **1991**, 30, 3027.
- Kuo, Y.-H.; King, M. L.; Chen, C.-F.; Chen, H.-Y.; Chen, C.-H.; Chen, K.; Lee, K.-H. *J. Nat. Prod.* **1994**, 57, 263.
- Zhen, Y.-L.; Xu, Y.; Lin, J.-F. *Acta. Pharm. Sin.* **1989**, 24, 568.
- Takaishi, Y.; Ujita, K.; Tokuda, H.; Nishino, H.; Iwashima, A.; Fujita, T. *Cancer Lett.* **1992**, 65, 19.
- (a) González, A. G.; Jimenez, I. A.; Ravelo, A. G.; Coll, J.; González, J. A.; Lloria, J. *Biochem. Syst. Ecol.* **1997**, 25, 513; (b) González, A. G.; Jimenez, I. A.; Ravelo, A. G.; Bazzocchi, I. L. *Tetrahedron* **1993**, 49, 6637.
- Duan, H.; Takaishi, Y.; Bando, M.; Kido, M.; Imakura, Y.; Lee, K. *Tetrahedron Lett.* **1999**, 40, 2969.
- Takaishi, Y.; Aihara, F.; Tamai, S.; Nakano, K.; Tomimatsu, T. *Phytochemistry* **1992**, 31, 3943.
- Smith, C. R.; Miller, R. W.; Weisleder, D.; Rohweder, W. K.; Eickman, N.; Clardy, J. *J. Org. Chem.* **1976**, 41, 3264.
- González, A. G.; Luis, J. G.; Grillo, T. A.; Vazquez, J. T. *J. Nat. Prod.* **1991**, 54, 579.
- Bryan, R. F.; Smith, R. M. *J. Chem. Soc. (B)* **1971**, 2159.
- (a) Barrett, H. C.; Büchi, G. *J. Am. Chem. Soc.* **1967**, 89, 5665; (b) Büchi, G.; Wuest, H. *J. Org. Chem.* **1979**, 44, 546.
- Marshall, J. A.; Pike, M. T. *J. Org. Chem.* **1968**, 33, 435.
- Asselin, A.; Mongrain, M.; Deslongchamps, P. *Can. J. Chem.* **1968**, 46, 2817.
- Heathcock, C. H.; Kelly, T. R. *J. Chem. Soc., Chem. Commun.* **1968**, 267.
- (a) Huffman, J. W.; Miller, C. A.; Pinder, A. R. *J. Org. Chem.* **1976**, 41, 3705; (b) Huffman, J. W.; Hillenbrand, G. F. *Tetrahedron Suppl.* **1981**, 9, 269; (c) Huffman, J. W.; Desai, R. C. *J. Org. Chem.* **1982**, 47, 3254; (d) Huffman, J. W.; Desai, R. C.; Hillenbrand, G. F. *J. Org. Chem.* **1984**, 49, 982; (e) Huffman, J. W.; Raveendranath, P. C. *J. Org. Chem.* **1986**, 51, 2148; (f) Huffman, J. W.; Raveendranath, P. C. *Tetrahedron* **1987**, 43, 5557.
- (a) White, J. D.; Cutshall, N. S.; Kim, T.-S.; Shin, H. *J. Am. Chem. Soc.* **1995**, 117, 9780; (b) White, J. D.; Shin, H.; Kim, T.-S.; Cutshall, N. S. *J. Am. Chem. Soc.* **1997**, 119, 2404.
- For recent synthetic studies by other research groups and us, see: (a) Spivey, A. C.; Woodhead, S. J.; Weston, M.; Andrews, B. I. *Angew. Chem., Int. Ed. Engl.* **2001**, 40, 769; (b) Boyer, F.-D.; Ducrot, P.-H. *Synthesis* **2000**, 13, 1868; (c) Descoins, Jr., C.; Thanh, G. V.; Boyer, F.-D.; Ducrot, P.-H.; Descoins, C.; Lallemand, J.-Y. *Synlett* **1999**, 2, 240; (d) Nan, F.; Liu, L.; Xiong, Z.; Chen, Y.; Li, T.; Li, Y. *Collect. Czech., Chem. Commun.* **1997**, 62, 1089; (e) Chen, X.; Nan, F.; Xiong, Z.; Shao, S.; Li, T.; Li, Y. *Collect. Czech., Chem. Commun.* **1995**, 60, 521; (f) Nan, F.; Chen, X.; Xiong, Z.; Li, T.; Li, Y. *Synth. Commun.* **1994**, 24, 2319; (g) Li, Y.; Chen, X.; Shao, S.; Li, T. *Indian J. Chem.* **1993**, 32, 356; (h) Chen, X.; Shao, S.; Li, T.; Li, Y. *Synthesis* **1992**, 1061.
- Zhou, G.; Gao, X.; Li, W. Z.; Li, Y. *Tetrahedron Lett.* **2001**, 42, 3101.
- The enantiomeric excess of **7** was determined by ^1H NMR analysis of the corresponding 9-hydroxy ester derivatives prepared by regioselective and stereospecific reduction with sodium borohydride and esterification with (*R*)-*O*-acetylmandelic acid, see: Parker, D. *J. Chem. Soc., Perkin Trans. 2* **1983**, 83.
- Mitsunobu, O. *Synthesis* **1981**, 1.
- Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, 48, 4156.
- Triacetate of **12** ($\text{R}=\text{Ac}$) gave poor facial selectivity for the catalytic hydrogenation (ca. 1: 3).
- An authentic sample is not available for direct comparison. Spectral data for **3**: IR (film) 3680, 3589, 3478, 2936, 2853, 1375, 1260, 1125, 1085, 1045, 850 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 1.20 (6H, s, 10- CH_3 , 11- CH_3), 1.25 (3H, d, $J=7.0$ Hz, 4- CH_3), 1.47 (3H, s, 11- CH_3), 3.21 (1H, m, 9-H), 4.17 (1H, brs, 1-H), 4.21 (1H, m, 2-H); ^{13}C NMR (100 MHz, CDCl_3) δ 90.5, 83.2, 79.3, 75.8, 66.7, 43.8, 35.5, 35.3, 34.1, 31.4, 30.1, 29.7, 24.8, 24.2, 15.5; MS (EI) m/z 270 (18%, M^+), 255(9), 252(10), 208(20), 179(12), 149(70), 125(55), 109(75), 69(100), 43(98); HRMS (EI): calcd for $\text{C}_{15}\text{H}_{26}\text{O}_4$: 270.1831, found 270.1825.